Soquelitinib for ALPS-FAS-related swelling and low blood counts
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests an investigational drug called soquelitinib to see if it can shrink enlarged lymph nodes and improve low blood cell counts in people with ALPS-FAS. It may offer a new treatment option for those who have active symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 16 years old.
- You must have a confirmed diagnosis of ALPS-FAS (a specific type of autoimmune disease).
- You must have at least one swollen lymph node or an enlarged spleen right now.
- If you take steroids, your dose must be stable and less than 20 mg per day for the last 4 weeks.
- You cannot have a serious active infection (like tuberculosis, HIV, or hepatitis) or have had certain cancers recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
Hear when a new Autoimmune Lymphoproliferative Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.